↓ Skip to main content

Antimalarials for treating rheumatoid arthritis

Overview of attention for article published in Cochrane database of systematic reviews, October 2000
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (74th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter
wikipedia
1 Wikipedia page

Citations

dimensions_citation
52 Dimensions

Readers on

mendeley
42 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Antimalarials for treating rheumatoid arthritis
Published in
Cochrane database of systematic reviews, October 2000
DOI 10.1002/14651858.cd000959
Pubmed ID
Authors

Maria E Suarez-Almazor, Elaine Belseck, Beverley Shea, Joanne Homik, George A Wells, Peter Tugwell

Abstract

To assess the short-term efficacy and toxicity of antimalarials for the treatment of rheumatoid arthritis (RA). We searched the Cochrane Musculoskeletal Group's trials register, the Cochrane Controlled Trials Register, Medline and Embase up to and including August 2000. We also carried out a handsearch of the reference lists of the trials retrieved from the electronic search. All randomized controlled trials (RCTs) and controlled clinical trials (CCTs) comparing antimalarials against placebo in patients with RA DATA COLLECTION AND ANALYSIS: Data abstraction was carried out independently by two reviewers. The same two reviewers using a validated checklist (Jadad 1996) assessed the methodological quality of the RCTs and CCTs. Rheumatoid arthritis outcome measures were extracted from the publications for the 6-month endpoint. The pooled analysis was performed using standardized mean differences for joint counts, pain and global assessments. Weighted mean differences were used for erythrocyte sedimentation rate (ESR). Toxicity was evaluated with pooled odds ratios for withdrawals. A chi-square test was used to assess heterogeneity among trials. Fixed effects models were used throughout. We found four trials, with 300 patients randomized to hydrochloroquine and 292 to placebo. Only trials evaluating hydroxychloroquine could be pooled in the analysis. A statistically significant benefit was observed when hydroxychloroquine was compared to placebo. The standardized mean differences for the various outcome measures ranged from -0.33 to -0.52, and were statistically significant. Statistically significant differences were also observed for ESR. Overall withdrawals and withdrawals due to lack of efficacy were significantly more frequent in the placebo group. No differences were observed in withdrawals due to toxicity. Hydroxychloroquine appears to be efficacious for the treatment of RA. Its overall effect appears to be moderate, but its low toxicity profile should be considered when treating patients with RA.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 2%
Unknown 41 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 8 19%
Researcher 7 17%
Other 6 14%
Student > Ph. D. Student 5 12%
Student > Doctoral Student 3 7%
Other 7 17%
Unknown 6 14%
Readers by discipline Count As %
Medicine and Dentistry 23 55%
Agricultural and Biological Sciences 3 7%
Nursing and Health Professions 2 5%
Chemistry 2 5%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Other 3 7%
Unknown 7 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 July 2018.
All research outputs
#3,449,607
of 13,309,886 outputs
Outputs from Cochrane database of systematic reviews
#6,316
of 10,550 outputs
Outputs of similar age
#40,835
of 166,505 outputs
Outputs of similar age from Cochrane database of systematic reviews
#59
of 111 outputs
Altmetric has tracked 13,309,886 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 10,550 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.8. This one is in the 38th percentile – i.e., 38% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 166,505 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 111 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.